STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G/A

ALLO Schedule 13G/A filing by Citadel Advisors

Citadel Advisors reported beneficial ownership of 6.9M shares, representing 2.8% of Allogene Therapeutics, Inc. in this filing.

FiledMay 15, 2026
Ownership dateMar 31, 2026
Reported shares6.9M
Reported ownership2.8%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 0
Shared voting power 6.9M
Sole dispositive power 0
Shared dispositive power 6.9M
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$2.00as of May 15, 2026
Latest tracked price$1.95as of Aug 5, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
Citadel Advisors
CIK
CIK0001423053
Accession
0001104659-26-062730
Form
Schedule 13G/A
Open SEC filing View ALLO ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →